WDNA
WisdomTree BioRevolution Fund
WDNA tracks a modified equally-weighted index of companies in developed markets that focus on the advancements in genetics and biotechnology.
International
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 2.6 M
ASSETS UNDER MGMT
45 bp
EXPENSES
Fund Basics
| Inception date | Jun 03, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| TWIST BIOSCIENCE CORP. | 5.5 % |
| MODERNA, INC. | 4.1 % |
| ELI LILLY & CO | 4.1 % |
| JOHNSON & JOHNSON | 2.9 % |
| UNITED THERAPEUTICS CORP | 2.7 % |
| BEAM THERAPEUTICS, INC. | 2.3 % |
| TEMPUS AI INC | 2.2 % |
| IMMUNOME, INC. | 2.2 % |
| STOKE THERAPEUTICS, INC. | 2.2 % |
| NATERA INC | 2.2 % |
Constituent Breakdown
| Number of holdings | 80 |
| Herfindahl-Hirschman Index | 193 |
| Wgt avg mkt cap (mns) | $91,466 |
| Large cap (>$10bn) | 48.0% |
| Mid cap ($2-10bn) | 31.0% |
| Small cap (<$2bn) | 15.7% |
| Developed mkts. | 96.1% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 80.5 % |
 |
BRITAIN | 3.9 % |
 |
SWITZERLAND | 3.3 % |
 |
GERMANY | 3.0 % |
 |
NETHERLANDS | 2.3 % |
 |
DENMARK | 1.8 % |
 |
BELGIUM | 0.7 % |
 |
AUSTRALIA | 0.6 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 22.0% | 50.4% | 14.2% | 5.7% | -5.1% | -- | -- | -3.7% |
| Dividend Yield | 0.0% | 0.0% | 0.4% | 0.5% | 0.4% | -- | -- | 0.4% |
| Total Returns | 22.0% | 50.4% | 14.6% | 6.3% | -4.7% | -- | -- | -3.4% | Ann. Volatility | 24.3% | 26.5% | 26.3% | 25.4% | 25.3% | -- | -- | 25.2% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.11 | 27% |
| MSCI EAFE | 0.95 | 31% |
| MSCI Emg Mkts | 0.49 | 17% |
Liquidity Measures
| Avg. volume (000) | 2 |
| ADV traded (mns) | $0 |
| Turnover | 1.5% |
| Avg. Bid/Ask (% of price) | 0.89% |
Technical Indicators
| 30d moving avg. (EMA) | $19.59 |
| Relative strength (RSI) | 62 |
| MACD/Signal | 0.78/0.73 |
| Bollinger Bands (Upper/Lower) | $22.12/$17.53 |
| Short interest (% of AUM) | 0.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. WDNA |
Expenses vs. WDNA |
ALTAR Score™ vs. WDNA |
|---|---|---|---|---|
| GNOM | Global X Genomics & Biotechnology ETF | 35.3% | +5 bp | 0.0% |
| HELX | Franklin Genomic Advancements ETF | 32.8% | +5 bp | +1.7% |
| XBI | State Street SPDR S&P Biotech ETF | 32.4% | -10 bp | +2.5% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 31.6% | -10 bp | -0.9% |
| IBB | iShares Biotechnology ETF | 28.7% | 0 bp | +2.1% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 27.1% | -26 bp | +2.9% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 27.0% | +15 bp | +9.6% |
| BBP | Virtus LifeSci Biotech Products ETF | 25.5% | +34 bp | -0.9% |
| BMED | Future Health ETF | 24.8% | +40 bp | +3.7% |
| HRTS | Tema Heart & Health ETF | 24.1% | +30 bp | +5.8% |
Risk and Returns: WDNA vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/16/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-2.7%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 418 funds in the International Equity category with an average
ALTAR Score™ of 6.5% and a standard deviation
of 1.7%. WDNA's ALTAR Score™ is approximately -5.3 standard
deviations above the category average. This places WDNA in the 1st percentile
among funds in the category.
Sell-Side Consensus
$21.96
PRICE TARGET
+10.7%
UPSIDE